Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,312.80
(
0.75%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.59
(
-0.06%
)
Bitcoin
73,953.18
(
0.01%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 92890

Monday, 03/22/2010 6:04:37 AM

Monday, March 22, 2010 6:04:37 AM

Post# of 257253
So, after careful consideration, the FDA accepted the Copaxone application from NVS/MNTA for review even though the FDA knew from the start that an ANDA was an inappropriate regulatory pathway for this application? You’re still not making any sense, IMHO.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up